Data / Drug companies / Carbinoxamine maleate
Carbinoxamine maleate: 9 companies and 10 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Carbinoxamine maleate is listed in the FDA National Drug Code Directory by 9 companies, with 10 products in commercial distribution. 8 of the products (80.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; suspension, extended release; solution, and the newest product started marketing on August 1, 2025.
The request: Get every company that lists carbinoxamine maleate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 9
- Products
- 10
- Generic (ANDA) products
- 8 (80.0%)
- Application numbers
- 6
- Routes
- Oral
- Brand names
- RyVent, Karbinal Er, Carbzah
- openFDA record search
- api.fda.gov
Companies that list carbinoxamine maleate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Genus Lifesciences | 2 | tablet; solution | Generic drugs (ANDA) | August 2, 2023 |
| Aytu Therapeutics, LLC | 1 | suspension, extended release | New drug applications (NDA) | January 3, 2014 |
| BioComp Pharma, Inc. | 1 | tablet | Generic drugs (ANDA) | May 27, 2011 |
| BluCrest Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | April 16, 2024 |
| Carwin Pharmaceutical Associates, LLC | 1 | tablet | Generic drugs (ANDA) | February 17, 2017 |
| Ipg Pharmaceuticals, Inc. | 1 | solution | Generic drugs (ANDA) | June 1, 2025 |
| Leading Pharma, LLC | 1 | tablet | Generic drugs (ANDA) | August 1, 2025 |
| Neos Therapeutics, LP | 1 | suspension, extended release | Authorized generics (NDA) | June 1, 2024 |
| Tripoint Therapeutics, LLC | 1 | tablet | Generic drugs (ANDA) | July 22, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 6 | 60% |
| Suspension, extended release | 2 | 20% |
| Solution | 2 | 20% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 8 | 80% |
| Authorized generics (NDA) | 1 | 10% |
| New drug applications (NDA) | 1 | 10% |
Pharmacologic classes
| Class | Products |
|---|---|
| Histamine-1 Receptor Antagonist | 10 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.